Liposomes as cytokine-supplement in tumor cell-based vaccines.

[1]  D. Crommelin,et al.  Sustained cytokine delivery for anticancer vaccination: liposomes as alternative for gene-transfected tumor cells. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[2]  E. Wagner,et al.  Cytokine gene-modified tumor cells for prophylactic and therapeutic vaccination: IL-2, IFN-gamma, or combination IL-2 + IFN-gamma. , 1998, Cytokines, cellular & molecular therapy.

[3]  H. Seigler,et al.  Eradication of melanoma pulmonary metastases by immunotherapy with tumor cells engineered to secrete interleukin-2 or gamma interferon. , 1997, Cancer gene therapy.

[4]  H. Maguire,et al.  Melanoma and vitiligo: immunology’s Grecian urn , 1996, Cancer Immunology, Immunotherapy.

[5]  S. Rosenberg,et al.  Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. , 1996, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[6]  G. Schaffner,et al.  Cancer vaccines: the interleukin 2 dosage effect. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[7]  K. Zatloukal,et al.  Elicitation of a systemic and protective anti-melanoma immune response by an IL-2-based vaccine. Assessment of critical cellular and molecular parameters. , 1995, Journal of immunology.

[8]  K. Zatloukal,et al.  Tumor vaccines: effects and fate of IL-2 transfected murine melanoma cells in vivo. , 1995, International journal of immunopharmacology.

[9]  K. Zatloukal,et al.  Somatic gene therapy for cancer: the utility of transferrinfection in generating 'tumor vaccines'. , 1993, Gene.

[10]  K Zatloukal,et al.  Coupling of adenovirus to transferrin-polylysine/DNA complexes greatly enhances receptor-mediated gene delivery and expression of transfected genes. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[11]  M. Mitchell.  Chemotherapy in combination with biomodulation: a 5-year experience with cyclophosphamide and interleukin-2. , 1992, Seminars in oncology.

[12]  E. Gilboa,et al.  Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity , 1990, The Journal of experimental medicine.

[13]  S. Martino,et al.  A phase I trial of recombinant interleukin-2 combined with recombinant interferon-gamma in patients with cancer. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  W. Boswell,et al.  Active-specific immunotherapy for melanoma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  R. Kurzrock,et al.  Clinical toxicity of interferons in cancer patients: a review. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.